Fig. 4: Three DODMA DOPE formulations with various compositions.
From: Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2
A Particle size, polydispersity index (PDI), zeta potential (ZP) and encapsulation efficiency. All LNPs were produced as described in “Methods”. B Body weight change following intramuscular immunizations. C Antibody profiling of d14, d28, and d42 plasma samples for anti-spike IgG reactivity. Statistical analysis was performed between 10% DSPC mRNA LNP group and other groups for each corresponding time point. *, p < 0.05; **, p < 0.01. Only significant p values are shown. N = 5 per group.
